Kezar Life Sciences Stock Price, News & Analysis

Kezar Life Sciences, Inc. (KZR) reported its financial results for Q4 and full year 2020, highlighting advances in its clinical programs despite challenges. The company’s lead candidate, KZR-616, is progressing in multiple trials, with FDA orphan drug designations granted for specific conditions. Financially, cash and equivalents rose to $140.4 million, while R&D expenses increased due to ongoing clinical trials, leading to a Q4 net loss of $10.9 million. Looking ahead, the company anticipates interim data from its key studies in 2021, supporting its strategic development goals.

Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotechnology company, announced CEO John Fowler's participation in the “Autoimmune/Complement” panel at the Cowen 41^st Annual Virtual Health Care Conference on March 3, 2021, at 11:40 AM EST. The event will be live for conference attendees. Kezar focuses on developing first-in-class therapies for rare autoimmune diseases and cancer, with lead candidate KZR-616 in Phase 2 trials for lupus nephritis and other conditions. KZR-261 is in IND-enabling activities targeting cancer.

Kezar Life Sciences (Nasdaq: KZR) announced that CEO John Fowler will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available on demand starting February 16 on their website. Additionally, Chief Scientific Officer Chris Kirk, Ph.D., will join a panel on drugging undruggable cancer targets. Kezar specializes in developing innovative treatments for immune-mediated and oncologic disorders, with lead candidate KZR-616 in Phase 2 trials for lupus nephritis, dermatomyositis, and polymyositis.

Kezar Life Sciences, a clinical-stage biotechnology company, announced that CEO John Fowler will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be available on January 11, 2021, at 6:00 am EST on the company’s website. Kezar is focused on developing breakthrough treatments for immune-mediated and oncologic disorders, including KZR-616, a first-in-class immunoproteasome inhibitor, and KZR-261 for cancer treatment. An archived replay will be accessible for 90 days post-conference.

Kezar Life Sciences (KZR) announced its inclusion in the NASDAQ Biotechnology Index, effective December 21, 2020. This index tracks biotechnology and pharmaceutical securities listed on the Nasdaq Stock Market. To qualify, companies must meet minimum market capitalization, trading volume, and public company seasoning requirements. Kezar focuses on developing innovative treatments for immune-mediated and oncologic disorders, including its first-in-class immunoproteasome inhibitor, KZR-616, and KZR-261, a candidate targeting cancer therapies.

Kezar Life Sciences (Nasdaq: KZR) announced upcoming presentations at two virtual investor conferences. The first event is the Jefferies Virtual London Healthcare Conference on November 18, 2020, featuring a fireside chat with CEO John Fowler, CSO Christopher Kirk, and CMO Noreen R. Henig. The second presentation will be at the 2020 Evercore ISI HealthCONx Conference on December 3, 2020, led by CEO John Fowler. Both presentations will be webcast live and archived on the company's website for 90 days.

Kezar Life Sciences, a clinical-stage biotechnology firm, presented promising data on KZR-616, an innovative immunoproteasome inhibitor, during the American College of Rheumatology Annual Meeting. Dr. Richard Furie's presentation revealed updated safety and efficacy signals for KZR-616 in systemic lupus erythematosus (SLE) with no new safety concerns. The drug displayed encouraging trends in disease activity scores and has been well tolerated during trials. Additionally, preclinical findings suggest KZR-616 might significantly aid in treating inflammatory myopathies. The ongoing clinical studies include MISSION and PRESIDIO trials.

Kezar Life Sciences, a clinical-stage biotechnology firm, has announced that the FDA has granted Orphan Drug Designation for KZR-616, targeting polymyositis (PM) and dermatomyositis (DM). PM and DM are rare autoimmune diseases affecting up to 51,000 and 71,000 individuals in the U.S., respectively. KZR-616 is a first-in-class selective immunoproteasome inhibitor aimed at addressing the underlying causes of these diseases. The designation may offer significant benefits, including marketing exclusivity and tax credits. A Phase 2 trial for KZR-616 is currently enrolling patients.

Kezar Life Sciences (Nasdaq: KZR) announced six presentations at four medical conferences, highlighting KZR-616, a selective immunoproteasome inhibitor, and its potential in treating immune-mediated diseases. Key presentations include interim results from the MISSION Phase 1b study on systemic lupus erythematosus (SLE) and preclinical data on KZR-616's mechanism of action. The company is also showcasing KZR-261, a protein secretion inhibitor, expected to enter IND submission for solid tumors in early 2021. These advancements underline Kezar's commitment to developing innovative therapies.